NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

Why Madrigal Pharmaceuticals (MDGL) Is Up 14.4% After Rezdiffra Patent Extension and Narrower Q2 Loss

Madrigal Pharmaceuticals recently reported its second quarter 2025 results, showing a much narrower net loss of US$42.28 million, down from US$151.97 million a year ago, alongside significant commercial progress for its lead product, Rezdiffra. The company also secured a new U.S. patent for Rezdiffra, extending exclusivity until February 2045, while advancing international expansion and pipeline development to further strengthen its market position. Let's examine how the newly extended...